BENEV Exosome Regenerative Complex+ for Hair Loss
What You Need to Know Before You Apply
What is the purpose of this trial?
This trial tests the effectiveness and safety of BENEV Exosome Regenerative Complex+ following a microneedling procedure for thinning hair. The goal is to determine if this combination can enhance hair thickness and quality over four months. Ideal participants are healthy men and women experiencing hair thinning without a diagnosed condition like telogen effluvium. Participants will receive monthly treatments and must maintain their usual hair care routine throughout the study. As an unphased trial, this study allows participants to contribute to innovative research that could lead to new solutions for hair thinning.
Do I have to stop taking my current medications for the trial?
The trial requires that you do not substantially change your current medications during the study. If your doctor advises you to change your medications, you must inform the clinic as soon as possible.
What prior data suggests that BENEV Exosome Regenerative Complex+ is safe for use with SylFirmX® RF microneedling?
Research has shown that the BENEV Exosome Regenerative Complex+, when combined with RF microneedling, is generally well-tolerated. Studies have found this combination effective and free from significant side effects for individuals with thinning hair. Participants in these studies did not report major negative effects, indicating the treatment's safety for scalp use. However, individual experiences may vary, so discussing any concerns with a healthcare provider is important.12345
Why are researchers excited about this trial?
Researchers are excited about BENEV Exosome Regenerative Complex+ for hair loss because it uses exosomes, which are tiny, naturally occurring vesicles that can promote hair growth by delivering growth factors and signals directly to hair follicles. Unlike traditional treatments like minoxidil or finasteride, which often take months to show results and have varying effectiveness, this treatment is applied post-microneedling to enhance the absorption and efficacy of the exosomes. This novel approach might offer faster and more targeted hair regeneration, potentially leading to quicker and more noticeable improvements in hair density and quality.
What evidence suggests that BENEV Exosome Regenerative Complex+ might be an effective treatment for hair loss?
Research has shown that BENEV Exosome Regenerative Complex+ may improve hair growth and quality. In one study, 97% of participants noticed better hair quality, and 83% saw noticeable hair growth by day 120. Another study found a small but significant increase in hair density, from 149.7 to 153.6 hairs per square centimeter, after four weeks. These results suggest that using this complex, especially with microneedling, could benefit those with thinning hair. Overall, early evidence supports its potential to enhance hair thickness and appearance.12346
Are You a Good Fit for This Trial?
This trial is for healthy men and women aged 18-65 who feel their hair is thinning. Participants will undergo a treatment combining BENEV Exosome Regenerative Complex+ with SylFirmX® RF microneedling monthly for four months, followed by a check-up.Inclusion Criteria
Exclusion Criteria
Timeline for a Trial Participant
Screening
Participants are screened for eligibility to participate in the trial
Treatment
Participants receive BENEV Exosome Regenerative Complex+ post SylFirmX RF microneedling procedure applied to the scalp monthly for 4 sessions
Follow-up
Participants are monitored for safety and effectiveness after treatment
What Are the Treatments Tested in This Trial?
Interventions
- BENEV Exosome Regenerative Complex+
Trial Overview
The study tests the effectiveness and safety of BENEV Exosome Regenerative Complex+ when used after SylFirmX® RF microneedling in treating self-perceived thinning hair. It requires four monthly treatments plus follow-up.
How Is the Trial Designed?
1
Treatment groups
Experimental Treatment
BENEV Exosome Regenerative Complex+® post SylFirmX® RF microneedling procedure applied to the scalp monthly for 4 sessions.
Find a Clinic Near You
Who Is Running the Clinical Trial?
Ablon Skin Institute Research Center
Lead Sponsor
Benev Company, Inc.
Industry Sponsor
Citations
NCT06571799 | Study Evaluating the Efficacy and Safety of ...
Exosomes can provide effective treatment for skin rejuvenation, scar reduction, hyperpigmentation, and hair growth. This new technology can be used alone but ...
An Exosome Regenerative Complex Plus Microneedling ...
On day 120, the investigator rating for improved hair quality was 97% and improved hair growth was 83%. Subject satisfaction with treatment ...
An Exosome Regenerative Complex Plus Microneedling ...
On day 120, the investigator rating for improved hair quality was 97% and improved hair growth was 83%. Subject satisfaction with treatment ...
4.
clinicaltrials.gov
clinicaltrials.gov/study/NCT06999408?term=AREA%5BConditionSearch%5D(%22Hair%20Diseases%22)&rank=4Efficacy and Safety of TargetCool + Benev Exosomes in ...
This clinical trial is testing a new approach to help improve hair thinning using a combination of cosmetic treatments. The purpose of the study is to learn ...
Advances in the extracellular vesicles treatment of alopecia
The mean hair density increased from 149.7 ± 13.7 hairs/cm2 at pre-treatment to 153.6 ± 16.8 hairs/cm2 at the 4th week (p = 0.043) and further ...
6.
ctv.veeva.com
ctv.veeva.com/study/study-evaluating-the-efficacy-and-safety-of-benev-exosome-regenerative-complex-for-self-perceived-tStudy Evaluating the Efficacy and Safety of BENEV Exosome ...
The goal of this clinical trial is to further substantiate the effectiveness and safety of BENEV Exosome Regenerative Complex+ post ...
Other People Viewed
By Subject
By Trial
Related Searches
Unbiased Results
We believe in providing patients with all the options.
Your Data Stays Your Data
We only share your information with the clinical trials you're trying to access.
Verified Trials Only
All of our trials are run by licensed doctors, researchers, and healthcare companies.